Ming-Gui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ming-Gui Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jian-Qing He
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
4 shared publications Yu Wang
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
3 shared publicationsMiao-Miao Zhang
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
2 shared publicationsShou-Quan Wu
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
2 shared publicationsShouquan Wu
Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Peoples R China
2 shared publicationsAndrew J Sandford
Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada
1 shared publication
Latest Publications
- 14 January 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (6) , 1716-1729
Plasma proteomics biomarkers for predicting anti‐tuberculosis drug‐induced liver injury: A comprehensive assessment
Aims: This study aims to identify predictive plasma protein biomarkers for anti‐tuberculosis drug‐induced liver injury (ATB‐DILI) and develop machine learning models for pre‐treatment risk stratification. Methods: In this retrospective nested case–control study, proteomic profiling of pre‐treatment plasma from 24 patients (12 ATB‐DILI, 12 controls) identified differentially expressed proteins, which were validated by ELISA in an independent cohort (35 ATB‐DILI, 37 controls). Multiple machine learning algorithms were implemented to develop clinical prediction models and evaluate the prognostic value of the identified protein biomarkers. Results: Proteomic analysis of pre‐treatment samples from the exploratory cohort identified five significantly differentially expressed proteins: antithrombin III, apolipoprotein D, carboxypeptidase B2, Chromogranin‐A, and Retinol‐binding protein 4. These proteins are functionally implicated in inflammatory responses, oxidative stress, and drug metabolism pathways. Validation using baseline plasma from an independent cohort confirmed consistent expression patterns for all five proteins ( p < 0.01), with directional changes matching the discovery phase findings. The random forest model, built on these pre‐treatment biomarkers, demonstrated robust predictive performance in the test set (AUC = 0.94, sensitivity = 90.0%, specificity = 90.0%, accuracy = 0.90). Importantly, consensus across multiple machine learning approaches (GBDT, SVM, GBM, etc.) confirmed predictive stability and generalizability of this protein signature (inter‐model AUC range: 0.85–0.96). Conclusion: This study has successfully identified five pre‐treatment plasma protein signature that, when incorporated into machine learning models, may enable the prediction of ATB‐DILI risk, offering potential for early intervention in tuberculosis therapy.
- 14 January 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (6) , 1716-1729
Plasma proteomics biomarkers for predicting anti‐tuberculosis drug‐induced liver injury: A comprehensive assessment
Aims: This study aims to identify predictive plasma protein biomarkers for anti‐tuberculosis drug‐induced liver injury (ATB‐DILI) and develop machine learning models for pre‐treatment risk stratification. Methods: In this retrospective nested case–control study, proteomic profiling of pre‐treatment plasma from 24 patients (12 ATB‐DILI, 12 controls) identified differentially expressed proteins, which were validated by ELISA in an independent cohort (35 ATB‐DILI, 37 controls). Multiple machine learning algorithms were implemented to develop clinical prediction models and evaluate the prognostic value of the identified protein biomarkers. Results: Proteomic analysis of pre‐treatment samples from the exploratory cohort identified five significantly differentially expressed proteins: antithrombin III, apolipoprotein D, carboxypeptidase B2, Chromogranin‐A, and Retinol‐binding protein 4. These proteins are functionally implicated in inflammatory responses, oxidative stress, and drug metabolism pathways. Validation using baseline plasma from an independent cohort confirmed consistent expression patterns for all five proteins ( p < 0.01), with directional changes matching the discovery phase findings. The random forest model, built on these pre‐treatment biomarkers, demonstrated robust predictive performance in the test set (AUC = 0.94, sensitivity = 90.0%, specificity = 90.0%, accuracy = 0.90). Importantly, consensus across multiple machine learning approaches (GBDT, SVM, GBM, etc.) confirmed predictive stability and generalizability of this protein signature (inter‐model AUC range: 0.85–0.96). Conclusion: This study has successfully identified five pre‐treatment plasma protein signature that, when incorporated into machine learning models, may enable the prediction of ATB‐DILI risk, offering potential for early intervention in tuberculosis therapy.
- Open Access
- 1 August 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 6365-6372
Association of Three SNPs Loci of Kelch-Like-ECH-Associated Protein 1 (Human) with Tuberculosis in Chinese Han Population
Purpose: Progression from latent tuberculosis infection (LTBI) to pulmonary TB (PTB) was associated with genetic polymorphisms, but there were limited genetic polymorphism data on LTBI and PTB. We aimed at examining the association of KEAP1 gene polymorphisms with PTB and LTBI. Patients and Methods: PTB patients and close contacts of PTB patients were recruited from West China Hospital of Sichuan University. After obtaining the patient’s consent, we draw 2– 5mL of blood from the patient’s peripheral vein. Tag-SNPs of KEAP1 were chosen according to previous studies. The genotyping was done by improved multiplex ligase detection reaction (iMLDR). We used logistic regression to assess the association of SNPs with LTBI/PTB, with sex and age as covariates. Results: A total of 209 PTB patients, 201 LTBI, and 204 HCS were included in the present study. Three Tag-SNPs were included in this study. Significant association was found for KEAP1 rs1048290 between LTBI and HCS. Compared with the KEAP1 rs1048290 CC genotype, genotype GC had an 38% decreased risk for development LTBI (P = 0.043, OR = 0.62, 95% CI: 0.039– 0.98). We also found that SNPs in KEAP1 were significantly related to PTB compared to LTBI. Compared with the rs11545829G allele, allele A had an 30% decreased risk for development PTB (P = 0.034, OR = 0.70, 95% CI: 0.51– 0.97). We also found the rs11668429 polymorphism was related to PTB. Compared with TT, GT had a significantly increased risk of LTBI developing into PTB (P = 0.041, OR = 1.68, 95% CI: 1.02– 2.77). Conclusion: Our study suggested that KEAP1 polymorphisms were significantly related to susceptibility to PTB and LTBI subjects.
- 1 August 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 6365-6372
Open AccessAssociation of Three SNPs Loci of Kelch-Like-ECH-Associated Protein 1 (Human) with Tuberculosis in Chinese Han Population
Purpose: Progression from latent tuberculosis infection (LTBI) to pulmonary TB (PTB) was associated with genetic polymorphisms, but there were limited genetic polymorphism data on LTBI and PTB. We aimed at examining the association of KEAP1 gene polymorphisms with PTB and LTBI. Patients and Methods: PTB patients and close contacts of PTB patients were recruited from West China Hospital of Sichuan University. After obtaining the patient’s consent, we draw 2– 5mL of blood from the patient’s peripheral vein. Tag-SNPs of KEAP1 were chosen according to previous studies. The genotyping was done by improved multiplex ligase detection reaction (iMLDR). We used logistic regression to assess the association of SNPs with LTBI/PTB, with sex and age as covariates. Results: A total of 209 PTB patients, 201 LTBI, and 204 HCS were included in the present study. Three Tag-SNPs were included in this study. Significant association was found for KEAP1 rs1048290 between LTBI and HCS. Compared with the KEAP1 rs1048290 CC genotype, genotype GC had an 38% decreased risk for development LTBI (P = 0.043, OR = 0.62, 95% CI: 0.039– 0.98). We also found that SNPs in KEAP1 were significantly related to PTB compared to LTBI. Compared with the rs11545829G allele, allele A had an 30% decreased risk for development PTB (P = 0.034, OR = 0.70, 95% CI: 0.51– 0.97). We also found the rs11668429 polymorphism was related to PTB. Compared with TT, GT had a significantly increased risk of LTBI developing into PTB (P = 0.041, OR = 1.68, 95% CI: 1.02– 2.77). Conclusion: Our study suggested that KEAP1 polymorphisms were significantly related to susceptibility to PTB and LTBI subjects.
- 1 July 2019
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 71, 54-59
Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance
- 1 July 2019
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 71, 54-59
Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance
- 1 March 2019
- Published by Elsevier in Microbial Pathogenesis
- Vol. 128, 288-293
Polymorphisms in the STAT4 gene and tuberculosis susceptibility in a Chinese Han population
- 1 March 2019
- Published by Elsevier in Microbial Pathogenesis
- Vol. 128, 288-293
Polymorphisms in the STAT4 gene and tuberculosis susceptibility in a Chinese Han population
- Open Access
- 1 June 2018
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 11, 873-887
Association between tobacco smoking and drug-resistant tuberculosis
Association between tobacco smoking and drug-resistant tuberculosis Ming-Gui Wang,1,* Wei-Wei Huang,1,* Yu Wang,1 Yun-Xia Zhang,1 Miao-Miao Zhang,1 Shou-Quan Wu,1 Andrew J Sandford,2 Jian-Qing He1 1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 2Centre for Heart Lung Innovation, University of British Columbia and St. Paul’s Hospital, Vancouver, BC, Canada *These authors contributed equally to this work Background: Tobacco smoking is a risk factor for tuberculosis but little is known about the relationship between tobacco smoking and drug-resistant tuberculosis (DR-TB). We undertook a systematic review and meta-analysis to quantitatively assess the association between DR-TB and tobacco smoking.Methods: We searched for relevant studies in the Ovid MEDLINE, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, WANFANG, and WEIPU databases from inception to September 1, 2017. Results were expressed as odds ratios (ORs) with accompanying 95% CIs, and subgroup analyses were performed by study design, smoking type, DR-TB type, and multivariate analysis.Results: Thirty-three studies related to tobacco smoking and DR-TB were included. We found substantial evidence that tobacco smoking is associated with an increased risk of DR-TB (OR 1.57, 95% CI 1.33–1.86). Associations were also found in subgroup analyses: for multidrug-resistant tuberculosis (OR 1.49, 95% CI 1.19–1.86) and for any DR-TB (OR 1.70, 95% CI 1.3–2.23); the pooled OR was 1.45 (95% CI 1.11–1.90) for current smoking, 2.25 (95% CI 1.46–3.47) for past smoking, and 1.56 (95% CI 1.22–1.98) for smoking history; and similar ORs were also observed in study design and multivariate analysis subgroup analysis.Conclusion: This study demonstrated that tobacco smoking is an independent risk factor for DR-TB. Keywords: tobacco smoking, drug-resistant tuberculosis, multidrug-resistant tuberculosis, MDR-TB, meta-analysis
- 1 June 2018
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 11, 873-887
Open AccessAssociation between tobacco smoking and drug-resistant tuberculosis
Association between tobacco smoking and drug-resistant tuberculosis Ming-Gui Wang,1,* Wei-Wei Huang,1,* Yu Wang,1 Yun-Xia Zhang,1 Miao-Miao Zhang,1 Shou-Quan Wu,1 Andrew J Sandford,2 Jian-Qing He1 1Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 2Centre for Heart Lung Innovation, University of British Columbia and St. Paul’s Hospital, Vancouver, BC, Canada *These authors contributed equally to this work Background: Tobacco smoking is a risk factor for tuberculosis but little is known about the relationship between tobacco smoking and drug-resistant tuberculosis (DR-TB). We undertook a systematic review and meta-analysis to quantitatively assess the association between DR-TB and tobacco smoking.Methods: We searched for relevant studies in the Ovid MEDLINE, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, WANFANG, and WEIPU databases from inception to September 1, 2017. Results were expressed as odds ratios (ORs) with accompanying 95% CIs, and subgroup analyses were performed by study design, smoking type, DR-TB type, and multivariate analysis.Results: Thirty-three studies related to tobacco smoking and DR-TB were included. We found substantial evidence that tobacco smoking is associated with an increased risk of DR-TB (OR 1.57, 95% CI 1.33–1.86). Associations were also found in subgroup analyses: for multidrug-resistant tuberculosis (OR 1.49, 95% CI 1.19–1.86) and for any DR-TB (OR 1.70, 95% CI 1.3–2.23); the pooled OR was 1.45 (95% CI 1.11–1.90) for current smoking, 2.25 (95% CI 1.46–3.47) for past smoking, and 1.56 (95% CI 1.22–1.98) for smoking history; and similar ORs were also observed in study design and multivariate analysis subgroup analysis.Conclusion: This study demonstrated that tobacco smoking is an independent risk factor for DR-TB. Keywords: tobacco smoking, drug-resistant tuberculosis, multidrug-resistant tuberculosis, MDR-TB, meta-analysis